Inter partes review

Robocast Announces That the USPTO Has Denied Unified Patents Inc. Petition for Inter Partes Review of '932 Patent

Retrieved on:

Friday, February 10, 2023

Music, Internet, Online, Technology, Entertainment, Patent, McKool Smith, Unified, United States Patent and Trademark Office, Patent Trial and Appeal Board, Netflix, NPE, Petition, Intellectual property, Inter partes review, IPR, PTAB, Generic drug, Robocasting

Robocast, a pioneering playlist technology company, announced today that on January 20, 2023, the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") denied a petition for inter partes review ("IPR"), IPR2022-01125, filed by Unified Patents Inc. against Robocast Inc.'s U.S. Patent No.

Key Points:

Robocast, a pioneering playlist technology company, announced today that on January 20, 2023, the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") denied a petition for inter partes review ("IPR"), IPR2022-01125, filed by Unified Patents Inc. against Robocast Inc.'s U.S. Patent No.
Robocast Inc. ("Robocast") was represented by powerhouse patent litigation firms McKool Smith and Cantor Colburn.
Unified Patents Inc., the self-proclaimed "anti-troll," incorrectly characterized Robocast as a Non-Practicing Entity ("NPE") in their failed challenge to the '932 Patent.
Accordingly, we deny the Petition and decline to institute an inter partes review."

Aurinia Announces PTAB Has Terminated Inter Partes Review

Retrieved on:

Wednesday, January 25, 2023

FDA, Health, Research, Pharmaceutical, Science, Biotechnology, Inter partes review, Patent Trial and Appeal Board, IPR, Patent, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., United, PTAB, Pharmaceutical industry, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036.

Key Points:

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036.

Heim, Payne & Chorush LLP Wins Key PTAB Ruling Against Technology Giants Apple, LG Electronics, Samsung

Retrieved on:

Friday, January 13, 2023

Patexia, Patent Trial and Appeal Board, Inter partes review, Federal Communications Commission, Patent, LG Electronics, Apple Inc., Electronics, LLP, FCC, Apple Inc. v. Samsung Electronics Co., Quanta Computer, Inc. v. LG Electronics, Inc., PTAB, Mobile phone, Arigna, Old Order German Baptist Brethren

The case before the PTAB is Apple Inc., LG Electronics, Inc., and Samsung Electronics Co., Ltd., Petitioners, v. Arigna Technology Ltd., Patent Owner, IPR2022-01037.

Key Points:

The case before the PTAB is Apple Inc., LG Electronics, Inc., and Samsung Electronics Co., Ltd., Petitioners, v. Arigna Technology Ltd., Patent Owner, IPR2022-01037.
The 24-page decision denied the inter partes review petition on all claims related to Arigna's U.S. Patent No.
Accurate power detection is critical in circuits that include power amplifiers to ensure compliance with Federal Communications Commission (FCC) regulations.
Heim, Payne & Chorush, LLP, represents plaintiffs and defendants in litigation across a broad range of technologies and business sectors.

AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent

Retrieved on:

Friday, January 20, 2023

Biotechnology, Pharmaceutical, Health, Medical Devices, Cell, IPR, Inter partes review, University, Patent, District court, UBC, JD, ABCL, PTAB, 3D printing, AbCellera

AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No.

Key Points:

AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No.
AbCellera’s ‘408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells.
“We are pleased with the PTAB’s decision, which reinforces the validity and strength of our microfluidic cell culture system patent claims,” said Tryn Stimart, JD, Chief Legal and Compliance Officer of AbCellera.
With the IPR outcomes, AbCellera intends to request that the district court resume its patent infringement cases against Berkeley Lights.”

VoIP-Pal’s Patent Infringement Lawsuit Against Amazon Remains in the Western District of Texas

Retrieved on:

Wednesday, January 11, 2023

6:21-cv-00668-ADA to deny transfer of the case to the Northern District of California.

Key Points:

6:21-cv-00668-ADA to deny transfer of the case to the Northern District of California.
§ 101 without prejudice to refiling after the January 26, 2023 status conferences.
On December 19, 2022, IPR2022-01072, and IPR2022-01073, filed against Patent No.
To date VoIP-Pal.com has successfully defeated 20 IPR challenges against 8 of its patents by Amazon, T-Mobile, Google, Apple, AT&T and Unified Patents.

The PTAB Denies Institution of All Four IPR Petitions filed by Amazon and T-Mobile; To Date VoIP-Pal.com Has Successfully Defeated 20 IPR Challenges Against 8 of its Patents by Amazon, T-Mobile, Google, Apple, AT&T and Unified Patents

Retrieved on:

Wednesday, December 28, 2022

Apple, IPR, Unified Patents, Patent Trial and Appeal Board, AT&T, AT, Inter partes review, PTAB, Amazon, T-Mobile, Mobile phone

To date, VoIP-Pal has successfully defeated 20 IPR challenges filed against 8 different patents by five companies, Unified Patents, Apple, AT&T, Google, and now Amazon and T-Mobile.

Key Points:

To date, VoIP-Pal has successfully defeated 20 IPR challenges filed against 8 different patents by five companies, Unified Patents, Apple, AT&T, Google, and now Amazon and T-Mobile.
These most recent decisions from the Patent Trial and Appeal Board will be posted on the Company’s website www.voip-pal.com .
CEO Emil Malak, said, “It is very encouraging to see our patents once again prevail on their technical merits at the PTAB.
I would like to take this opportunity to wish all of our shareholders a happy and healthy new year.

HCMC Announces Decision On Inter Partes Review (IPR) of Patent From PTAB

Retrieved on:

Wednesday, December 21, 2022

OTC Markets Group, Patent, IPR, Philip Morris, United States Court of Appeals for the Federal Circuit, PTAB, Inter partes review, Patent Trial and Appeal Board, Hearing, Tobacco

HOLLYWOOD, FL, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Healthier Choices Management Corp. (OTC Pink: HCMC) (“HCMC” or the “Company”) announced today that the U.S. Patent and Trademark's Office (USPTO) Patent Trial and Appeal Board (PTAB) issued a Final Written Decision in connection with the inter partes review (IPR) of U.S. Patent No.

Key Points:

HOLLYWOOD, FL, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Healthier Choices Management Corp. (OTC Pink: HCMC) (“HCMC” or the “Company”) announced today that the U.S. Patent and Trademark's Office (USPTO) Patent Trial and Appeal Board (PTAB) issued a Final Written Decision in connection with the inter partes review (IPR) of U.S. Patent No.
10,561,170 (the “Patent”).
The PTAB found that all claims of the Patent are not patentable.
The Patent remains valid and enforceable until appeals have been exhausted.

The PTAB Denies Institution of All Four IPR Petitions by Google; To Date VoIP-Pal.com Has Successfully Defeated 16 IPR Challenges Against 8 of its Patents by Google, Apple, AT&T and Unified Patents

Retrieved on:

Wednesday, December 21, 2022

Apple, IPR, Unified Patents, Patent Trial and Appeal Board, The St. Regis Mohawk Tribe and Restasis patent, Family, AT&T, AT, Inter partes review, PTAB, Mobile phone

To date, VoIP-Pal has successfully defeated 16 IPR challenges filed against 8 different patents by four companies, Unified Patents, Apple, AT&T, and now Google.

Key Points:

To date, VoIP-Pal has successfully defeated 16 IPR challenges filed against 8 different patents by four companies, Unified Patents, Apple, AT&T, and now Google.
These most recent decisions from the Patent Trial and Appeal Board will be posted on the Company’s website www.voip-pal.com .
We appreciate the support of our shareholders as we continue to work hard in pursuing a fair resolution.
He was a patriotic American who served directly under four U.S. Presidents, Richard Nixon, Gerald Ford, Ronald Reagan, and George H.W.

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

Retrieved on:

Tuesday, January 3, 2023

Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Patent, Sun Pharma, IPR, Inter partes review, Generic drug, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review (IPR) directed at Aurinia’s U.S. Patent No.

Key Points:

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review (IPR) directed at Aurinia’s U.S. Patent No.
10,286,036, as well as settlement of the ongoing patent infringement litigation in the United States (U.S.) related to Sun’s CEQUA® product.
Under the settlement agreement, which is contingent upon the U.S. Patent Trial and Appeal Board approving the joint motion to terminate the IPR, both parties agreed to dismiss their claims and counterclaims against each other and cease bringing any future further action against the other.

ITC Issued Final Determination: CARKU Won 337 Investigation

Retrieved on:

Friday, September 16, 2022

ITC, NOCO, United States International Trade Commission, IPR, Hearing, History, Complaint, Patent Trial and Appeal Board, USITC, PTAB, Hostile witness, Patent, Inter partes review, Tobacco, Generic drug, Animal

New York, New York--(Newsfile Corp. - September 16, 2022) - On August 29, 2022, ITC issued final determination that CARKU won final ruling victory and the ITC judge found that Carku's product do not infringe NOCO's 024 patent.

Key Points:

New York, New York--(Newsfile Corp. - September 16, 2022) - On August 29, 2022, ITC issued final determination that CARKU won final ruling victory and the ITC judge found that Carku's product do not infringe NOCO's 024 patent.
Click to read more about ITC final determination: https://usitc.gov/system/files/secretary/fed_reg_notices/337/337_1256_no...
In January 2021, the NOCO company filed a complaint at the U.S. International Trade Commission (USITC) requesting for a Section 337 investigation on the jump starter industry for patent infringement of NOCO patents.
Since then, the ITC investigation has involved 44 companies, including CARKU.
For the reasons stated above, on August 29, 2022,ITC issued the final determination that CARKU won the "337"patent infringement case.